InterMed acquires omega-3 strains
This article was originally published in The Tan Sheet
Executive Summary
Natural product firm InterMed Discovery acquires "unique microbial omega-3 fatty acid production strains and related know-how" from the University of Saarland, the Dortmund, Germany-based firm says Aug. 19. IMD says the strains offer a "more favorable ratio" of docosahexaenoic acid and eicosapentaenoic acid. The firm expects to spearhead a research and development initiative with the university to achieve omega-3 formulations allowing for new pharmaceutical, food and supplement product applications. Financial terms were not disclosed
You may also be interested in...
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.